Literature DB >> 14501259

R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model.

C Sánchez1, P Gruca, M Papp.   

Abstract

The selective serotonin (5-HT) reuptake inhibitor, citalopram, is a racemic mixture of the stereoisomers, S-(+)-citalopram (escitalopram) and R-(-)-citalopram (R-citalopram). R-citalopram has been shown to counteract the 5-HT enhancing properties of escitalopram in acute studies in animals. In the present study we report, for the first time, on an interaction between R-citalopram and escitalopram after repeated dosing in a rat chronic mild stress (CMS) model of depression. The effect of escitalopram (2.0, 3.9 and 7.8 mg/kg per day), R-citalopram (7.8 mg/kg per day) and escitalopram 3.9 mg/kg per day plus R-citalopram 7.8 mg/kg per day were studied and compared to the effect of citalopram (8.0 mg/kg per day), imipramine and R-fluoxetine (8.9 mg/kg per day). Significant effects relative to a vehicle-treated group were achieved from week 1 for escitalopram (3.9 and 7.8 mg/kg per day), from week 2 for citalopram (8.0 mg/kg per day), from week 3 for R-fluoxetine (8.9 mg/kg per day) and from week 4 for escitalopram (2.0 mg/kg per day) and imipramine (8.9 mg/kg per day). R-citalopram (7.8 mg/kg per day) and escitalopram (3.9 mg/kg per day) plus R-citalopram (7.8 mg/kg per day) did not differ significantly from vehicle. There were no drug-induced effects in non-stressed control groups. In conclusion, escitalopram showed a shorter time to response in the rat CMS model of depression than citalopram, which was faster acting than R-fluoxetine and imipramine. R-citalopram counteracted the effect of escitalopram. The mechanism of action of R-citalopram is, at the moment unclear, but may be relevant to the improved clinical antidepressant activity seen with escitalopram in comparison with citalopram, and may also indicate an earlier response to escitalopram compared to other selective serotonin reuptake inhibitors (SSRIs).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501259     DOI: 10.1097/01.fbp.0000087733.21047.60

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  21 in total

1.  Oxidative parameters in the rat brain of chronic mild stress model for depression: relation to anhedonia-like responses.

Authors:  Chao Wang; He-Ming Wu; Xiao-Rong Jing; Qiang Meng; Bei Liu; Hua Zhang; Guo-Dong Gao
Journal:  J Membr Biol       Date:  2012-07-08       Impact factor: 1.843

2.  High-fat diet-induced metabolic disorders impairs 5-HT function and anxiety-like behavior in mice.

Authors:  Juliane Zemdegs; Gaël Quesseveur; David Jarriault; Luc Pénicaud; Xavier Fioramonti; Bruno P Guiard
Journal:  Br J Pharmacol       Date:  2015-12-09       Impact factor: 8.739

3.  Chronic treatment with escitalopram but not R-citalopram translocates Galpha(s) from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound.

Authors:  Lanqiu Zhang; Mark M Rasenick
Journal:  J Pharmacol Exp Ther       Date:  2009-12-08       Impact factor: 4.030

4.  Specific effects of escitalopram on neuroendocrine response.

Authors:  Emily R Hawken; James A Owen; Robert W Hudson; Nicholas J Delva
Journal:  Psychopharmacology (Berl)       Date:  2009-08-07       Impact factor: 4.530

5.  In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.

Authors:  N Klein; J Sacher; T Geiss-Granadia; T Attarbaschi; N Mossaheb; R Lanzenberger; C Pötzi; A Holik; C Spindelegger; S Asenbaum; R Dudczak; J Tauscher; S Kasper
Journal:  Psychopharmacology (Berl)       Date:  2006-09-06       Impact factor: 4.530

Review 6.  Escitalopram: a review of its use in the management of anxiety disorders.

Authors:  Sohita Dhillon; Lesley J Scott; Greg L Plosker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.

Authors:  Jacob P R Jacobsen; Per Plenge; Benjamin D Sachs; Alan L Pehrson; Manuel Cajina; Yunzhi Du; Wendy Roberts; Meghan L Rudder; Prachiti Dalvi; Taylor J Robinson; Sharon P O'Neill; King S Khoo; Connie Sanchez Morillo; Xiaodong Zhang; Marc G Caron
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

8.  Antidepressant-like activity of zinc: further behavioral and molecular evidence.

Authors:  Magdalena Sowa-Kućma; Beata Legutko; Bernadeta Szewczyk; Kinga Novak; Paweł Znojek; Ewa Poleszak; Mariusz Papp; Andrzej Pilc; Gabriel Nowak
Journal:  J Neural Transm (Vienna)       Date:  2008-09-03       Impact factor: 3.575

9.  Chronic unpredictable stress promotes neuronal apoptosis in the cerebral cortex.

Authors:  Alessia Bachis; Maria Idalia Cruz; Rachel L Nosheny; Italo Mocchetti
Journal:  Neurosci Lett       Date:  2008-07-03       Impact factor: 3.046

10.  Molecular pathways associated with stress resilience and drug resistance in the chronic mild stress rat model of depression: a gene expression study.

Authors:  A Bergström; M N Jayatissa; T Thykjaer; O Wiborg
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.